OSTROV GERALD M
Known title: DirectorCIK: 0001534739
OSTROV GERALD M's purchase track record
OSTROV GERALD M has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/13/2022 | ENTX | $27K | -4.7% | -49.1% | -18.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ENTX | ▲ Buy | Grant | 28,721 | $0 | 1/1/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 8,038 | $0 | 1/15/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 8,452 | $0 | 10/2/2024 | View on chart |
| ENTX | ▲ Buy | Grant | 20,446 | $0 | 8/27/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 10,000 | $27K | 1/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor
Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.